aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview

aTyr Pharma

03/08/2026 12:44

aTyr Pharma Inc ATYR.OQ ATYR.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for aTyr Pharma Inc is for a loss of 12 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 5.6% in the last three months. ​
Wall Street's median 12-month price target for aTyr Pharma Inc is $3.50, about 620.6% above its last closing price of $0.49
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.13
-0.14
-0.11
Beat
20
Dec. 31 2026
-0.10
-0.18
-0.14
Beat
23.8
Sep. 30 2025
-0.19
-0.18
-0.26
Missed
-41.6​
Jun. 30 2025
-0.18
-0.18
-0.22
Missed
-19.3
​​Mar. 31 2025
-0.18
-0.19
-0.17
Beat
10.5
Dec. 31 2024
-0.21
-0.23
-0.18
Beat
20.4​
Sep. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5
Jun. 30 2024
-0.24
-0.24
-0.23
Beat
3.4
This summary was machine generated August 3 at 11:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)